Premium
Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
Author(s) -
Antill Yoland,
Buchanan Daniel D.,
Scott Clare L.
Publication year - 2022
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.34024
Subject(s) - medicine , endometrial cancer , immune system , oncology , cancer , immune checkpoint , cancer research , immunology , immunotherapy
Lay Summary Endometrial cancer is common, and a subset recurs and requires additional treatment. Some of these are recognized as being susceptible to immune therapies and are said to have mismatch repair deficiency (dMMR). However, this clinical trial highlights which cases are more likely to respond well: those containing mutations in genes known as Lynch genes and also some with mutations in POLE/POLD1 (“ultra‐hypermutation” genes). In contrast, the majority of dMMR endometrial cancers have silencing or DNA methylation of one of these genes, MLH1 , and do not seem to be as responsive to single‐agent immune therapy. The availability of combination therapies may be important to consider for these women.